[Results of a prospective open study of therapy of sudden deafness with flunarizine].
The treatment effect of the lipophilic calcium antagonist flunarizine on the recovery of sudden hearing loss was evaluated in a prospective phase-II study. Thirty-seven patients presenting with recent and sudden onset of unilateral sensorineural hearing loss were treated with 50 mg flunarizine intravenously for the first two days followed by 10 mg flunarizine orally for four weeks. Pure-tone audiometry was done before the beginning of the treatment and after one and four weeks. The absolute and relative hearing gains after one and four weeks were compared to those of 67 similar patients previously treated with saline infusions and placebo tablets in the same institutions during a double blind study (Probst et al. Acta Otolaryngol. 112 (1992) 435-443). The mean absolute hearing gains of the flunarizine group was 17 dB and 21 dB, after one and four weeks respectively (placebo group: 16 dB and 24 dB). The corresponding relative hearing gains (defined as absolute gain divided by initial hearing loss) were 35% and 43% for the flunarizine group and 33% and 42% for the placebo group. We conclude that flunarizine treatment does not improve the recovery of sudden hearing loss.
Meier
R
R
HNO-Klinik, Kantonsspital, Aarau.
Tschopp
K
K
Podvinec
M
M
Grossenbacher
R
R
Ermanni
D
D
Probst
R
R
D000284:Administration, Oral; D001309:Auditory Threshold / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005444:Flunarizine / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003639:Hearing Loss, Sudden / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged
D005444:Flunarizine
Ergebnisse einer prospektiven offenen Studie zur Therapie des Hörsturzes mit Flunarizine.